公司概况 - 公司是动物健康行业的重要参与者，提供增强动物护理的产品和服务 [1] - 公司由首席执行官 Jeff Simmons 领导，其专注于推动增长并维持强劲的市场地位 [1] 股价表现与市场数据 - Stifel Nicolaus 设定目标价为27美元，较当前价格21.91美元有约23.26%的潜在上涨空间 [2][6] - 股票当前交易价格为21.94美元，小幅下跌2.49%，变动额为0.56美元 [2] - 股票日内交易区间为21.38美元至22.98美元，过去一年最高价为22.96美元，最低价为8.02美元，波动显著 [4] - 公司市值约为109亿美元，体现了其在行业内的重要地位 [4][6] - 股票交易量为9,189,975股，显示出活跃的投资者兴趣 [5] 管理层观点与公司战略 - 首席执行官强调即使在困难的经济时期，消费者也愿意在动物护理上消费，这对公司增长至关重要 [3] - 管理层认为上述消费者行为表明对公司产品的需求稳定 [3][6] - 公司专注于资源分配，以维持其市场地位 [3]

So joining me now in a first on CNBC interview is Ela Co. Animal Health CEO Jeff Simmons. Jeff, we've spoken numerous times before.At this point, you know, I have multiple dogs in my household. Like many millions of Americans, we care about their health. What's been driving Ela Co's results, specifically when it comes to the pets versus the farm side of things.>> Yeah, Dom, thanks for the time. Yeah, we delivered a great quarter. 9% organic constant currency growth.That really marks uh nine consecutive quar ...

Elanco Animal Health (NYSE:ELAN) Q3 2025 Earnings Call November 05, 2025 08:00 AM ET Company ParticipantsJeff Simmons - President and CEOBob VanHimbergen - CFOTiffany Kanaga - VP of Investor RelationsJon Block - Managing DirectorDaniel Clark - VP of Equity ResearchUmer Raffat - Senior Managing DirectorConference Call ParticipantsLinda Bolduc - AnalystNone - AnalystMichael Ryskin - Managing Director and Senior Equity Research AnalystAndrea Alfonso - Equity AnalystBrandon Vazquez - Research AnalystNavann Ty - ...

Elanco Animal Health (NYSE:ELAN) Q3 2025 Earnings Call November 05, 2025 08:00 AM ET Company ParticipantsJeff Simmons - President and CEOBob VanHimbergen - CFOTiffany Kanaga - VP of Investor RelationsJon Block - Managing DirectorDaniel Clark - VP of Equity ResearchUmer Raffat - Senior Managing DirectorConference Call ParticipantsLinda Bolduc - AnalystNone - AnalystMichael Ryskin - Managing Director and Senior Equity Research AnalystAndrea Alfonso - Equity AnalystBrandon Vazquez - Research AnalystNavann Ty - ...

Elanco Animal Health (NYSE:ELAN) Q3 2025 Earnings Call November 05, 2025 08:00 AM ET Speaker0Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health's third quarter 2025 earnings conference call. At this time, all lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number one on your keypad. If you would like to ...

D 2025 Earnings – Third Quarter November 5, 2025 2025 | Q3 Earnings Notices and Disclaimers Forward-Looking Statements. This presentation contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements concerning product launches and revenue from such products, our 2025 full year and fourth quarter guidance, long-term expectations, our expectations regarding debt levels, and expectations regarding our industry and our operations, performance a ...

INDIANAPOLIS, Nov. 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the third quarter of 2025, provided guidance for the fourth quarter of 2025, and updated guidance for the full year 2025. "Thank you to our global team and customers as Elanco delivered strong results ahead of expectations, with an unrelenting focus on growth, innovation, and cash," said Jeff Simmons, President and CEO of Elanco. "Organic constant currency revenue growth of 9% refle ...

公司业务与市场地位 - 公司是动物健康行业的重要参与者，为宠物和牲畜提供广泛的产品和服务 [1] - 公司在驱虫药、诊断学和皮肤病学领域以创新解决方案闻名 [1] - 尽管面临行业竞争，公司仍保持强大的市场地位 [1][6] 财务业绩表现 - 2025年第三季度调整后每股收益为1.70美元，超过市场普遍预期的1.62美元 [2] - 调整后净利润达到7.54亿美元，按报告基准计算增长5%，按有机运营基准计算增长9% [3] - 季度销售额为24亿美元，同比增长1%，但略低于预期的24.1亿美元 [3] - 增长主要由驱虫药、诊断学和皮肤病学产品组合的成功驱动 [3] 投资机构观点与股价表现 - Stifel Nicolaus于2025年11月4日设定公司目标股价为140美元，较当时约125.50美元的交易价有约11.56%的潜在上涨空间 [2] - 当前股价为126.06美元，较前期高点下跌约12.67% [5] - 当日股价在122.03美元的低点和128.11美元的高点之间波动 [5] - 公司市值约为558.7亿美元，成交量为7,642,200股 [5] 面临的挑战 - 用于骨关节炎疼痛的单克隆抗体产品（如犬用Librela和猫用Solensia）销售额出现下滑 [4] - 牲畜产品销售额下降9%，原因是剥离了药物饲料添加剂产品组合 [4]

Zomedica posts highest quarterly revenue ever and record year-over-year revenue for 19th straight quarter! ANN ARBOR, MI / ACCESS Newswire / November 4, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2025. ...

PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began serving as President and CEO of the Company, succeeding Michael F. Brigham. At its ...